Welcome to the all-new Vetlearn

  • Vetlearn is becoming part of NAVC VetFolio.
    Starting in January 2015, Compendium and
    Veterinary Technician articles will be available on
    NAVC VetFolio. VetFolio subscribers will have
    access to not only the journals, but also:
  • Over 500 hours of CE
  • Community forums to discuss tough cases
    and networking with your peers
  • Three years of select NAVC Conference
    Proceedings
  • Free webinars for the entire healthcare team

To access Vetlearn, you must first sign in or register.

registernow

  Sign up now for:
Become a Member

Equine January/February 2009 (Vol 4, No 1)

Pathophysiology of Osteoarthritis

by Jorge Carmona, MVZ, MSc, PhD, Marta Prades, DVM, PhD, DACVS, DECVS

    CETEST This course is approved for 3.0 CE credits

    Start Test

    Abstract

    Osteoarthritis (OA) in horses is a chronic, degenerative process. Affected horses typically have clinical evidence of synovitis, varying degrees of lameness, and progressive loss of joint function. The inciting cause of OA remains unclear; however, factors such as repeated episodes of trauma, joint instability, synovitis-capsulitis, hypoxia and neovascularization, genetic predisposition, and obesity have been related to its development. The biochemical mediators that are synthesized in affected joints are of an inflammatory nature and include catabolic cytokines and enzymes that degrade cartilage and subchondral bone matrix. Although horses with OA can be recognized clinically and treated symptomatically, it is also important for clinicians to understand the cellular and molecular mechanisms involved in the pathologic process. A thorough understanding of the pathophysiology of the disease can aid clinicians in managing osteoarthritic patients.

    Osteoarthritis (OA), also known as degenerative joint disease, is the most common joint disease that affects humans,1 horses,2,3 and dogs.4 OA is a chronic, degenerative process characterized by progressive cartilage deterioration, subchondral bone remodeling, loss of joint space, marginal osteophytosis, and loss of joint function.1-5 Although the etiology of OA may differ across species or among individuals within a species, some components of the pathophysiology of the disease are consistent.1,3,4

    Several theories have been proposed to explain the origin of this disease. Independent of the initiating cause, however, the development of OA is consistently associated with a cascade of biochemical events mediated by cytokines, proteolytic enzymes, and other proinflammatory substances (e.g., prostaglandins, leukotrienes, nitric oxide). These mediators are responsible for the pathologic features of the disease, which include osteolysis, subchondral bone sclerosis, osteophytosis, articular cartilage erosion, and synovial membrane thickening.5-7 Irrespective of the initiating cause or initial point of injury, eventually all components of the joint become involved in the process. This article summarizes the relevant molecular aspects of the etiopathogenesis of OA and potential therapeutic molecular targets for controlling this disease.

    Pathogenic Mechanisms

    Several pathogenic mechanisms have been proposed to be involved in the development of OA. They include subchondral bone overload, joint instability (loss of mechanical integrity), synovitis-capsulitis, hypoxia, body mass index as it relates to obesity, and heredity.

    Subchondral Bone Overload (Mechanical Stress)

    A typical finding in horses that exercise at speed is subchondral sclerosis of bone in joints subjected to high weight-bearing impact and shear forces (e.g., carpus and fetlock).3,5 It has been postulated that articular overload, especially of subchondral bone, produces microtrauma, remodeling, hardening, and displacement of the osteochondral line.5 These changes reduce the elasticity and energy-dissipation capacity of the articular cartilage during locomotion.3 Furthermore, the injured tissue fails to heal because of the combined effects of high-impact exercise protocols, a lack of adequate warm-ups and post-exercise stretching, inadequate development of proprioception, working musculoskeletal tissue while it is fatigued, poor neuromuscular training, and inadequate rest intervals.8 The results of these forces are mechanical lesions that affect the joint tissue and its extracellular matrix (ECM),3 which may account for the common finding of OA in fetlock joints of performance horses or in knee joints of human athletes.5 However, OA also affects non-weight-bearing joints, such as those in the hands, spine, shoulders, and temporomandibular joints in humans and other mammals. Consequently, this theory does not completely explain the origin of these lesions, although either misalignment of articular surfaces or abnormalities of deep ligamentous components in the spinal and temporomandibular joints9 may result in abnormal load distribution.

    Joint Instability (Loss of Mechanical Integrity)

    Joint instability can be due to increased ligament laxity, a tear or strain in a ligament (FIGURE 1), or poor conditioning of the muscles that affect the joints. An example of the latter is the increased incidence of OA in the knees of humans with poor development of their quadriceps muscles.1 Training or racing can create episodes of increased joint laxity, especially when work is performed while an athlete is fatigued. It has been proposed that mechanoreceptors associated with joints lose their efficacy during fatigue, thereby impairing proprioceptive function and increasing the likelihood of injury.10

    Joint instability can also occur as the result of intense synovitis that generates excessive amounts of synovial fluid.1,3,5 It has been postulated that the increase in pressure within the joint may produce direct mechanical cartilage damage and anomalous overload forces of subchondral bone regions, thereby perpetuating synovitis.3 In humans, subtle mechanical instability produced by partial traumatic transection of the cranial anterior ligament of the knee can produce OA changes 1 year after the traumatic event.11 This may also occur in horses with posttraumatic arthritis with subtle mechanical impairment of soft tissue periarticular structures. Joint instability is an important cause of OA and should always be considered in affected patients, especially sport horses.

    Synovitis-Capsulitis

    The synovitis (i.e., histologic evidence of synovial membrane inflammation) that occurs in horses with OA2,3,7 can be a primary phenomenon, a consequence of joint trauma or articular overload, or an aftereffect of intraarticular drug injection or infection.3,5,6 The cells that make up the synovial membrane are a rich source of several proinflammatory molecules that can incite and perpetuate articular deterioration if the underlying cause of the inflammation cannot be controlled.1 Because the synovial membrane provides no mechanical protection to the joint, trauma or inflammation of adjacent structures (e.g., joint capsule, ligaments, muscles, tendons) could initiate synovitis and the subsequent development of OA.3,5,6

    Hypoxia

    A consistent finding during the development of OA is neovascularization, which initially involves the synovial membrane and subsequently the subchondral bone and cartilage.6,7 Although this ingrowth of new vessels increases the delivery of nutrients to the stressed articular cartilage and subchondral bone,1,6 it also contributes to the development of synovitis. In humans, hypoxia is a common component in the pathophysiology of OA and rheumatoid arthritis because the oxygen gradient across articular cartilage may be altered as a result of cartilage thinning and erosion, changes in ECM composition, and the development of cartilage fissures.12

    In OA and rheumatoid arthritis, exaggerated expression and limited degradation of two nuclear hypoxia-inducible factors (a1 and a2) occur. The resulting increase in these factors promotes the expression of two angiogenic peptides called vascular endothelial growth factor and platelet-derived cellular endothelial growth factor. Both peptides increase neovascularization and promote vascular permeability in the joint tissue, resulting in edema, protein vascular leakage, inflammation, and cartilage damage.6,12

    Body Mass Index/Leptin

    Leptin, a cytokine produced by white adipocytes, regulates appetite, energy expenditure, and the activity of the physes and the metabolism of bone. Leptin also promotes cellular proliferation and increases the metabolic activity of chondrocytes.9 It has recently been demonstrated that the plasma concentration of leptin is positively correlated with body mass index in humans with OA.13 Furthermore, increased plasma concentration of leptin has been shown to correlate positively with the severity of articular damage in rats.13 To date, there are no reported studies regarding the role of leptin in OA in horses. However, leptin is positively correlated with a high body mass index (obesity) in horses.14

    Hereditary Osteoarthritis

    In humans, OA occurs as a consequence of a genetic defect in collagen type-II (Col-II) assemblage, and there has been speculation regarding genetic mutations in other collagen-type codifying genes.15 To date, there is no evidence of a genetic basis for the development of OA in horses.

    Biochemical Events and Pathobiologic Consequences

    At the molecular level, OA is the result of an imbalance between the peptides that promote the synthesis of components of the ECM of articular cartilage and those that induce remodeling of these components. It has been proposed that the overall health of a joint depends on adequate expression of several growth factors.2,4,7 For example, transforming growth factor β (TGF-β)16,17 and insulin-like growth factors (IGFs)18-20 increase synthesis of the ECM. In contrast, cytokines such as interleukin-1 (IL-1) and tumor necrosis factor α (TNF-α) promote chemotaxis and degranulation of leukocytes and increased expression of additional proinflammatory mediators, including prostaglandin E2 (PGE2), leukotriene B4 (LTB4), bradykinin, and nitric oxide.1-4 IL-1 and TNF-α also increase the activity of several proteolytic enzymes that degrade articular cartilage, most notably the matrix metalloproteinases (MMPs).21-23 Collectively, these substances perpetuate synovitis,2,3,6 initiate articular cartilage damage,1-5 and induce remodeling of subchondral bone.2,8,9

    The pathogenesis of OA is orchestrated by a network of overlapping complex molecular mechanisms, resulting in damage to the tissue comprising the joint.1-5 To facilitate the understanding of the most important molecules involved in these processes, we discuss them as either catabolic or anabolic molecules.

    Catabolic Molecules

    Degradation of articular cartilage in the osteoarthritic degenerative process is due to complex interactions and up-regulation of several catabolic molecules, as summarized in TABLE 1 .1-5 However, the exact mechanism that triggers the development of OA remains obscure.

    Proinflammatory Cytokines

    Interleukin 1

    IL-1 is actually a family of three cytokines composed of two agonist peptides, IL-1α and IL-1β, and the IL-1 receptor antagonist protein (IL-1ra). The biologic effects of the two IL-1 agonist peptides are initiated by binding to a specific receptor.24 Although this same receptor can bind IL-1ra with a similar affinity, it does so without initiating a biologic effect.25 It has been proposed that IL-1β is one of the most important catabolic cytokines involved in OA.1,2,6 The proform of IL-1β is converted inside the cell by IL-1-converting enzyme (also called caspase 1) to produce the active form of IL-1β.1 The active form of IL-1β then promotes expression of an important transcription factor called nuclear factor k-b.4 This factor moves into the nucleus, where it interacts with the promoter regions of several genes and participates in up-regulation of genes, including those that produce secondary proinflammatory peptides (e.g., IL-6, IL-8, IL-12), chemokines, LTB4, PGE2, MMPs, and nitric oxide.1,4,21 IL-1β also inhibits the metabolic pathways in chondrocytes that are used to repair damaged ECM2; releases proteoglycans from ECM into the synovial fluid3; inhibits collagen type II (Col-II), IX (Col-IX), and XI (Col-XI) synthesis; stimulates production of abnormal proteoglycan molecules; and down-regulates expression of the natural inhibitors of MMPs, called tissue inhibitors of metalloproteinases (TIMPs).4,21,26-28

    While IL-1 has been considered the main stimulator of the degenerative joint disease process, recent information may refute this hypothesis. In an experimental model of OA that used knockout mice that lacked the IL-1 gene, lesions and evidence of accelerated cartilage catabolism developed in the lateral tibial plateau of stifle joints that had not undergone surgery.29 Furthermore, synthesis of MMP-3 initially increased when human chondrocytes were cultured with alginate beads and IL-1, and then synthesis decreased.30 In addition, recent evidence from studies using an in vitro model of equine cartilage degeneration31 shows that catabolic cytokines (i.e., IL-1 and TNF-α) are solely responsible for initiation of focal cartilage degeneration in OA.31 These findings suggest that IL-1 plays an important regulatory role in maintaining normal homeostasis in cartilage turnover but that its role in OA initiation and progression is perhaps not as critical as previously thought.

    An important part of the research on OA has been IL-1β blockade. The use of gene therapy with the IL-1ra encoding gene has been evaluated in experimentally induced OA in horses. Although the results of this research were encouraging, the effects were transient (28 days), and synovial inflammation occurred as a secondary complication.32 In a different approach, promising results have been obtained using an IL-1-converting enzyme inhibitor (pralnacasan) in an experimental model of OA in rats.1

    Tumor Necrosis Factor α

    TNF-α is secreted by macrophages, chondrocytes, synoviocytes, and osteoclasts as a membrane-bound precursor (latent form) that is activated by a specific TNF-α-converting enzyme.26-28 There is evidence that this enzyme is present in an increased concentration in humans with OA27; the same may be true in horses. TNF-α induces its biologic effects by interacting with two families of membrane receptors—TNF receptor types 1 and 2. There is convincing immunologic evidence for the presence of type 1 TNF receptors in the ECM of cartilage in osteoarthritic humans27 and in synovial membrane and noncalcified cartilage in an endotoxin-induced model of synovitis/arthritis in horses.28

    Although TNF-α seems to have catabolic effects similar to those of IL-1 on articular cartilage,1-3,26 it appears that TNF-α plays a more important role in the pathophysiology of rheumatoid arthritis.1,6,26 In fact, an important way of reducing the effects of TNF-α activity on articular cartilage in humans with rheumatoid arthritis has been administration of specific anti-TNF-α antibodies.27 These antibodies have not been used in treating OA.

    Extracellular Matrix-Degrading Enzymes

    Several enzymes that degrade ECM are up-regulated by IL-1β and TNF-α. The principal enzymes associated with degradation of ECM in cartilage are the MMPs, aggrecanases, serine proteases, aspartic proteases, and cysteine proteases. Whereas MMPs and serine proteases act at a neutral pH, aspartic proteases and cysteine proteases have greater activity at an acid pH.1,2,6 Relevant details about these enzymes and their capability to degrade ECM substrates in cartilage are summarized in TABLE 2 . An imbalance in the production of these enzymes, namely excessive and uncontrolled production, results in irreversible damage to joint tissues and self-perpetuation of the vicious cycle.

    Metalloproteinases

    MMPs belong to a zinc-dependent group of endopeptidases and can be secreted by synoviocytes, chondrocytes, macrophages, and neutrophils. Several members of this family, including collagenases (MMP-1, MMP-8, MMP-13), gelatinases (MMP-2, MMP-9), and stromelysins (MMP-3, MMP-10, MMP-11), are involved in the pathophysiology of OA.21-23,33 These enzymes are secreted as inactive zymogens that are activated by enzymatic cleavage of their catalytic region, which contains the active zinc-binding site. The effects of the specific MMP depend on the activity levels of the enzymes and the presence of inhibitors such as TIMPs and a2-macroglobulin.2,3

    MMP-1 and MMP-13 play prominent roles in the development of OA.7,21,33 MMP-1 is produced primarily by synovial cells that line the joints, and MMP-13 is a product of chondrocytes that reside in the cartilage. MMP-13 degrades the proteoglycan molecule aggrecan, giving it a dual role in matrix destruction.22 Up-regulation of other MMPs, such as MMP-2, MMP-3, and MMP-9, is also increased in OA, and these enzymes degrade noncollagen matrix components in joints. Although there has been considerable effort to design compounds that effectively inhibit either the synthesis or activity of MMPs and thereby minimize connective tissue destruction within joints, these efforts have not been successful.22

    Aggrecanases

    Aggrecanases, which are also called a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS), include 19 members that are numbered ADAMTS 1 through 20; there is no ADAMTS-11 because early reports of it were later found to describe ADAMTS-5. Aggrecanase-1 (ADAMTS-4) and aggrecanase-2 (ADAMTS-5) are the proteolytic enzymes that appear to degrade aggrecans in cartilage in OA.34 Aggrecanases cleave the aggrecan core protein and thus play an important role in the pathophysiology of OA. Synthesis of ADAMTS-4 and ADAMTS-5 in chondrocytes appears to be regulated by IL-1β, and there is convincing evidence that IL-1β down-regulates the synthesis of aggrecanase-1 under certain conditions.1,4 In an experimental model of canine OA, it was observed that a dual inhibitor (licofelone) of the lipoxygenase and cyclooxygenase pathways also inhibited the synthesis of aggrecanases.35 To our knowledge, this inhibitor has not been used in horses.

    Serine Proteases

    Plasminogen activator, bradykinin, plasmin, trypsin, cathepsin G, and elastase are important members of the serine protease family,3 as they can directly cleave ECM molecules. However, the principal catabolic effect of these enzymes is to activate latent proteases, such as the pro-MMPs.2 There is evidence that IL-1β may promote the action of these enzymes through PGE2-mediated up-regulation of plasminogen activator.3 Bradykinin is an important mediator of synovitis, and a specific bradykinin B2-receptor antagonist has recently yielded encouraging results in treating OA in human knees.1

    Eicosanoids

    Eicosanoids, such as prostaglandins, thromboxanes, and leukotrienes, are metabolites of arachidonic acid that are produced by inflammatory cells, chondrocytes, and synoviocytes. These substances are present in inflamed joints, primarily as the possible result of up-regulation of cyclooxygenase-2 (COX-2) by catabolic cytokines.1-4 PGE2 has important effects in the inflammatory process because it promotes vascular dilation, reduces the threshold for painful stimuli, facilitates up-regulation of plasminogen activator, and promotes degradation of proteoglycans.3,21 However, PGE2 also has antiinflammatory effects by up-regulating expression of antiinflammatory cytokines (TABLE 3) and down-regulating expression of catabolic cytokines and MMPs.3 Therefore, it has been postulated that PGE2 is a necessary component in controlling the inflammatory process.36

    Leukotrienes, which are produced via the lipoxygenase pathway, cause vasodilation and chemotaxis. There is convincing evidence for the involvement of leukotrienes, specifically LTB4, in the pathogenesis of arthritis. For example, the density of LTB4 type II receptors is increased in synovial membranes of humans with rheumatoid arthritis,37 suggesting that leukotrienes have an important role in the development of synovitis. Furthermore, a positive correlation has been identified between the number of leukocytes and the concentration of LTB4 in synovial fluid in horses with joint disease.38 Collectively, these findings would lend credence to studies comparing LTB4 receptor density in synovial membranes in normal horses and in horses with OA as well as to studies designed to test the efficacy of specific lipoxygenase inhibitors or LTB4 receptor antagonists in horses with OA.4

    Inhibition of eicosanoid synthesis is a cornerstone in treating OA in humans and animals. NSAIDs and corticosteroids have been used for this purpose and produce symptomatic relief of pain and synovial effusion. However, neither form of treatment alters progression of the disease. It is well recognized that corticosteroids are potent antiinflammatories, but they also have effects on not only joints but also metabolism and immunologic responses at a systemic level. Furthermore, corticosteroids produce catabolism of articular cartilage, especially when they are administered repeatedly.

    Nitric Oxide

    Nitric oxide, an inflammatory mediator synthesized by several cell types in joints, diminishes the deposition of sulfate into glycosaminoglycan chains, reduces collagen synthesis, interferes with up-regulation of the IL-1 receptor antagonist,7,39 decreases the activity of growth factors such as TGF-β and IGF-I, and has been postulated to be associated with aberrant apoptosis of chondrocytes in the pathogenesis of OA.40,41 Stimulation of chondrocytes by either endotoxin or IL-1β activates the inducible form of nitric oxide synthase (iNOS) and its associated enzymes.1 Although it does not appear that local iNOS expression plays a key role in the development of synovitis in horses,39 positive correlations (that were not apparent in normal horses) have been demonstrated among articular cartilage damage, chondrocyte apoptosis, and high immunoreactivity to nitrotyrosine (a protein that is closely associated with cellular production of nitric oxide) in osteoarthritic horses.40 In addition to nitric oxide, other free radicals, including superoxide, peroxide, and hydroxyl, are produced as part of the inflammatory response within joints. In turn, these mediators can act on chondrocytes and synovial fibroblasts, modifying their biosynthesis of proteoglycans, collagen, and hyaluronan as well as promoting release of catabolic mediators.3,6 The administration of nitric oxide synthase inhibitors in experimentally induced OA has resulted in reduction of synovial inflammation and destruction of cartilage and bone.1

    Clinical Signs Associated with Osteoarthritis Catabolic Molecules

    It has been postulated that horses with OA have different degrees of pain, synovial effusion, and functional impairment,3 reflecting the effects of the aforementioned catabolic molecules and tissues that comprise joints.3,6 Pain is generally manifested as lameness, which is the result of joint inflammation, exposure of subchondral bone, neovascularization and neoreinnervation, and increased osseous intramedullary pressure.6 There is no correlation between the apparent degree of pain and the severity of articular lesions.5 The primary network of nociceptors in joints (polymodal mechanoreceptors) is localized in the joint capsule, with receptor types I, II, and III predominating. In contrast, subchondral bone and synovial membrane have a more discrete distribution of type IV (unmyelinated endings) nociceptors, which play an important role in the perception of pain in patients with OA.6,42

    Type IV nociceptors are stimulated by lactate, potassium ions, quinines, serotonin, PGE2, and histamine.6,43 These stimuli result in the production of several tachykinins41 (e.g., substance P,43 neurokinin A, neuropeptide Y), calcitonin gene-related peptide, vasoactive intestinal peptide, and other substances.42,44,45 These substances stimulate the release of inflammatory mediators that perpetuate the inflammatory response, which is called neurogenic inflammation.1,6,42-44 Substance P is the main neuropeptide related to inflammation of articular cartilage.1,6,40 Substance P and other neuropeptides have been immunolocalized in the synovial subintimae of healthy and arthropathic horses.43 Substance P intensifies articular catabolism and synovial inflammation because it causes up-regulation of IL-1, MMPs, and PGE2.42-44 Substance P also produces synovial hyperplasia, local vasodilation, and extravasation of leukocytes and protein in innervated areas.43 The results of a study involving a canine model of OA suggest that antagonism of substance P with an analogue of the anticonvulsant gabapentin reduced synthesis of MMPs 1, 3, and 13 and iNOS without causing adverse systemic effects.45 These findings suggest that substance P may be a viable therapeutic target in treating OA.

    Joint effusion occurs as a consequence of synovitis; as blood flow increases, plasma proteins leak into the interstitium, and synovial fluid production increases.6 Although moderate synovitis may have a positive effect on the nutrition of articular cartilage, severe synovial effusion adversely affects joint function.5,6 Moreover, this degree of effusion can lead to fibrosis of the joint capsule, which, in turn, impairs joint function, thereby causing mechanical lameness.3,5

    Anabolic Molecules

    During the development of OA, an array of growth factors and cytokines are produced to counteract the catabolic effects exerted primarily by IL-1β and MMPs.1 Unfortunately, the effects of the catabolic molecules predominate, resulting in the development of severe OA. The principal peptide growth factors that have anabolic and antiinflammatory effects in joints are summarized in TABLE 3 .

    Growth Factors

    Growth factors are multifunctional peptides that have anabolic and proliferative effects on chondrocytes and their surrounding ECM. Of the many growth factors identified in the pathophysiology of OA process, the most important appear to be the families of IGF and TGF-β.6-20 It has been postulated that lesser known anabolic growth factors, such as platelet-derived growth factor and fibroblastic growth factor, could also be important in the disease.2

    Insulin-like Growth Factors

    IGFs are two molecules (IGF-I and IGF-II) that belong to the insulin family and are produced primarily by the liver; these factors are also synthesized by other cell types, including those in cartilage.18-20 The primary reserve of IGFs is plasma. IGF-I is transported by six binding proteins that modulate its biologic action.46 Although IGF-I is expressed in abundance in foal cartilage, its level of expression is diminished in older horses.19 IGF-I promotes differentiation of fetal chondrocytes and maintenance of ECM synthesis. In adult cartilage, IGF-I antagonizes IL-1β and reduces catabolism of ECM.2,19,20 With aging, the concentration of IGF-I required to maintain adequate synthesis of ECM increases dramatically.47 Although the results of in vitro studies indicate that the supraphysiologic concentration of IGF-I does not affect either chondrocyte survival or the quality of the ECM, intraarticular injection of IGF-I promotes tissue repair.2 This approach was tested in horses with experimentally induced cartilage defects, and the results indicated that intraarticular injection of IGF-I produced better evidence of cartilage repair than was seen in joints that were not injected with IGF-I.48 Anabolic and mitogenic effects of IGF-II have been demonstrated in IL-1-conditioned equine cartilage, suggesting that this peptide may have positive effects in horses.20 To date, however, no in vivo studies using IGF-II have been conducted in horses.

    It is important to note that although the IGF-I concentration is increased in horses with naturally occurring OA,49 expression of a specific IGF-binding protein that reduces the activity of IGF-I is also increased.50 It is possible that antagonism of this binding protein may provide an alternative therapeutic approach to the use of IGF-I alone.

    Transforming Growth Factor β

    Members of the TGF-β superfamily include TGF-β1, TGF-β2, TGF-β3, and a variety of bone morphogenetic proteins.2 It has been postulated-‚that TGF-β has anabolic and proliferative effects on articular cartilage and antagonizes the catabolic effects of IL-1β; however, TGF-β is less potent than IGF-I or IGF-II in this regard.18-20 There is conflicting information about the anabolic effects of TGF-β,4,6 primarily because this peptide has been associated with disorders in ECM synthesis (e.g., imbalances in proteoglycan assemblage) and promotes the synthesis of fibromodulin over that of biglycan and decorin.51 In addition, TGF-β promotes osteophyte formation in joints.6 Although osteophytes can perpetuate the local inflammatory response, it has been postulated that they promote stability of joints.6 Thus, TGF-β may have two roles in the pathophysiology of OA.4,6

    Antiinflammatory Cytokines

    Several antiinflammatory cytokines are produced as part of the inflammatory response and modulate the effects of catabolic cytokines and other inflammatory metabolites. The most important of these include IL-1ra, IL-4, IL-10, and IL-132,26,27 (TABLE 3). IL-1ra blocks IL-1 catabolic effects by coupling its membrane receptor. IL-4, IL-10, and IL-13 up-regulate IL-1ra expression. The use of an equine autologous conditioned serum rich in IL-1ra was evaluated in an equine OA model by Frisbie et al.52 This treatment significantly improved clinical lameness and the histologic appearance of the synovial membrane of the treated horses compared with those of the placebo group.

    Therapeutic Use of Growth Factors

    Anabolic growth factors, specifically IGF-I and TGF-β1, and certain antiinflammatory cytokines, most notably IL-1ra have been evaluated in several animal models of OA for their ability to induce regenerative changes in joints. These growth factors have been tested either by direct intraarticular injection of recombinant peptides or by gene therapy.32 Although the results obtained with purified growth factors and gene therapy are promising, significant economic restrictions are likely to reduce their use in equine practice. Additional research is needed to determine optimal doses of growth factors, and gene therapy has been used only experimentally.

    Platelet concentrates have been used as an autologous source of growth factors, primarily TGF-β1 and IGF-I, in humans undergoing maxillofacial or orthopedic surgery.53,54 This approach has been used in horses, with intraarticular injection of platelet concentrates being used to treat horses with severe joint disease.55 The results of this study were encouraging, with the treated horses having evidence of reduced lameness and joint effusion for 8 months without additional therapies. As with other forms of treatment, larger clinical trials that include appropriate control treatments will need to be conducted to determine whether this treatment will be effective in horses with OA.

    Conclusion

    Appreciation of the molecular mechanisms involved in the pathophysiology of OA makes it easier to understand why many symptomatic approaches to the treatment of this disease have failed. It is important to note, however, that many of the relevant studies to date have been conducted using either in vitro systems or laboratory animal models. Because OA is common in horses, future equine studies may provide the best means of evaluating new treatments7 that could be used in humans. There is considerably more to learn regarding the pathophysiology and treatment of OA. Biologic manipulation of cells, peptides, and genes directly related to this disease is providing exciting new ways to arrest the progression of OA and restore joint function.

    Downloadable PDF

    1. Wieland HA, Michaelis M, Kirshbaun BJ, et al. Osteoarthritis: an untreatable disease? Nat Rev Drug Disc 2005;4:331-344.

    2. Platt D. Articular cartilage homeostasis and the role of growth factors and cytokines in regulating matrix composition. In: McIlwraith CW, Trotter GW, eds. Joint Disease in the Horse. Philadelphia: WB Saunders; 1996:29-40.

    3. McIlwraith CW. General pathobiology of the joint and response to injury. In: McIlwraith CW, Trotter GW, eds. Joint Disease in the Horse. Philadelphia: WB Saunders; 1996:40-70.

    4. Yves H, Sánchez C, Balligand M. Pharmaceutical and nutraceutical management of canine osteoarthritis: present and future perspectives. Vet J 2005;170:113-123.

    5. Pool RR. Pathologic manifestations of joint disease in the athletic horse. In: McIlwraith CW, Trotter GW, eds. Joint Disease in the Horse. Philadelphia: WB Saunders; 1996:87-104.

    6. Bonnet DS, Walsh DA. Osteoarthritis, angiogenesis and inflammation. Rheumatology 2005;44(1):7-16.

    7. McIlwraith WC. Use of synovial fluid and serum biomarkers in equine bone and joint disease: a review. Equine Vet J 2005;37(5):473-482.

    8. Kawkak CE, McIIwraith CW, Norrdin RW, et al. The role of subchondral bone in joint disease: a review. Equine Vet J 2001;33(2):120-126.

    9. Loeser RF. Systemic and local regulation of articular cartilage metabolism: where does leptin fit in the puzzle? Arthritis Rheum 2003;48(11):3009-3012.

    10. Solomonow M, Krogsgaard M. Sensorimotor control of knee stability. A review. Scand J Med Sci Sports 2001;11(2):64-80.

    11. Nelson F, Billinghurst RC, Pidoux I, et al. Early post-traumatic osteoarthritis-like changes in human articular. Osteoarthritis Cartilage 2006;14(2):114-119.

    12. Giatromanolaki A, Sivridis E, Maltezos E, et al. Upregulated hypoxia inducible factor-1 and 2a pathway in rheumatoid arthritis and osteoarthritis. Arthritis Res Ther 2003;5(4):193-201.

    13. Dumond H, Presle N, Terlain B, et al. Evidence for a key role of leptin in osteoarthritis. Arthritis Rheum 2003;48(11):3118-3129.

    14. Buff PR, Dodss AC, Morrison CD, et al. Leptin in horses: tissue localization and relationship between peripheral concentrations of leptin and body condition. J Anim Sci 2002:2942-2948.

    15. Prockop DJ. Heritable osteoarthritis: diagnosis and possible modes of cell and gene therapy. Osteoarthritis Cartilage 1994;7(4):364-366.

    16. Fortier LA, Nixon AJ, Mohammed HO, et al. Altered biological activity of equine chondrocytes cultured in a three-dimensional fibrin matrix and supplemented with transforming growth factor beta-1. Am J Vet Res 1997;58(1):66-70.

    17. Iqbal J, Dudhia J, Bird JL, et al. Age-related effects of TGF-β on proteoglycan synthesis in equine articular cartilage. Biochem Biophys Res Commun 2000;274(2):467-471.

    18. Frisbie DD, Sandler EA, Trotter GW, et al. Metabolic and mitogenic activities of insulin-like growth factor-1 in interleukin-1-conditioned equine cartilage. Am J Vet Res 2000;61(4):436-441.

    19. Nixon AJ, Brower-Toland BD, Sandel LJ. Primary nucleotide structure of predominant and alternate splice forms of equine insulin-like growth factor I and their gene expression patterns in tissues. Am J Vet Res 1999;60(10):1234-1241.

    20. Davenport-Goodall CL, Boston RC, Richardson DW. Effects of insulin-like growth factor-II on the mitogenic and metabolic activities of equine articular cartilage with and without interleukin 1-b. Am J Vet Res 2004;65(2):238-244.

    21. Tung JT, Arnold CE, Alexander LH, et al. Evaluation of the influence of prostaglandin E2 on recombinant equine interleukin-1b-stimulated matrix metalloproteinases 1, 3, and 13 and tissue inhibitor of matrix metalloproteinase 1 expression in equine chondrocyte cultures. Am J Vet Res 2002;63(7):987-993.

    22. Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: role in arthritis. Front Biosci 2006;11:529-543.

    23. Brama PA, van den Boom R, DeGroott J, et al. PR Collagenase-1 (MMP-1) activity in equine synovial fluid: influence of age, joint pathology, exercise and repeated arthrocentesis. Equine Vet J 2004;36(1):34-40.

    24. Howard RD, McIlwraith CW, Trotter GW, et al. Cloning of equine interleukin 1a and equine interleukin 1b and determination of their full-length cDNA sequences. Am J Vet Res 1998;59(6):704-711.

    25. Howard RD, McIlwraith CW, Trotter GW, et al. Cloning of equine interleukin 1 receptor antagonist and determination of its full-length cDNA sequence. Am J Vet Res 1998;59(6):712-716.

    26. Punzi L, Calí² L, Plebani M. Clinical significance of cytokine determination in synovial fluid. Crit Rev Clin Lab Sci 2002;39(1):63-88.

    27. Fernandes JC, Martell-Pelletier J, Pelletier JP. The role of cytokines in osteoarthritis pathophysiology. Biorheology 2002;39(1-2):237-246.

    28. Todhunter PG, Kincaid SA, Todhunter RJ, et al. Immunohistochemical analysis of an equine model of synovitis-induced arthritis. Am J Vet Res 1996;57(7):1080-1093.

    29. Clements KM, Price JS, Chambers MG, et al. Gene deletion of either interleukin-1beta, interleukin-1beta-converting enzyme, inducible nitric oxide synthase, or stromelysin 1 accelerates the development of knee osteoarthritis in mice after surgical transection of the medial collateral ligament and partial medial meniscectomy. Arthritis Rheum 2003;48(12):3452-3463.

    30. Sanchez C, Mateus MM, Defresne MP, et al. Metabolism of human articular chondrocytes cultured in alginate beads. Long-term effects of interleukin 1beta and nonsteroidal antiinflammatory drugs. J Rheumatol 2002;29(4):772-782.

    31. Little CB, Flannery CR, Hughes CE, et al. Cytokine induced metalloproteinase expression and activity does not correlate with focal susceptibility of articular cartilage to degeneration. Osteoarthritis Cartilage 2005;13(2):162-170.

    32. Frisbie DD, Ghivizzani SC, Robbins PD, et al. Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther 2002;9(1):12-20.

    33. van den Boom R, Brama PA, Kiers GH, et al. The influence of repeated arthrocentesis and exercise on matrix metalloproteinase and tumor necrosis factor α activities in normal equine joints. Equine Vet J 2004;36(2):155-159.

    34. Tang BL. ADAMTS: a novel family of extracellular matrix proteases. Int J Biochem Cell Biol 2001;(1):33-44.

    35. Pelletier JP, Boileau C, Boily M, et al. The protective effect of licofelone on experimental osteoarthritis is correlated with the downregulation of gene expression and protein synthesis of several major cartilage catabolic factors: MMP-13, cathepsin K and aggrecanases. Arthritis Res Ther 2005;7:R1091-R1102.

    36. Gilroy DW, Colville-Nash PR, Willis D, et al. Inducible cyclooxygenase may have antiinflammatory properties. Nature 1999;5(6):698-701.

    37. Hashimoto A, Endo H, Hayasi I, et al. Differential expression of leukotriene B4 receptor subtypes (BLT1 and BLT2) in human synovial tissues and synovial fluid leukocytes of patients with rheumatoid arthritis. J Rheumatol 2003;30(8):1712-1718.

    38. Bertone AL, Palmer JL. Synovial fluid cytokines and eicosanoids as markers of joint disease in horses. Vet Surg 2001;30(6):528-538.

    39. Simmons EJ, Bertone AL, Hardy J, et al. Nitric oxide synthase activity in healthy and interleukin 1b-exposed equine synovial membrane. Am J Vet Res 1998;60(6):714-716.

    40. Kim DY, Taylor HW, Moore RM, et al. Articular chondrocyte apoptosis in equine osteoarthritis. Vet J 2003;166(1):52-57.

    41. Blanco FJ, Guitian R, Vazques-Martul E, et al. Osteoarthritis chondrocytes die by apoptosis. Arthritis Rheum 1998;41(2):284-289.

    42. Caron JP. Neurogenic factors in joint pain and disease pathogenesis. In: McIlwraith CW, Trotter GW, eds. Joint Disease in the Horse. Philadelphia: WB Saunders; 1996:70-80.

    43. Kirker-Head CA, Chandna VK, Agarwal RK, et al. Concentrations of substance P and prostaglandin E2 in synovial fluid of normal and abnormal joints of horses. Am J Vet Res 2000;61(6):714-718.

    44. O'Connor TM, O'Connell J, O'Brien DI, et al. The role of substance P in inflammatory disease. J Cell Physiol 2004;201(2):167-180.

    45. Boileau C, Martel-Pelletier J, Brunet J, et al. Oral treatment with PD-0200347, an a2d ligand, reduces the development of experimental osteoarthritis by inhibiting metalloproteinases and inducible nitric oxide synthase gene expression and synthesis in cartilage chondrocytes. Arthritis Rheum 2005;52(2):488-500.

    46. Harridge SDR. Ageing and local growth factors in muscle. Scand J Med Sci Sports 2003;13(1):34-39.

    47. Platt D, Bayliss MT. Proteoglycan metabolism of equine articular cartilage and its modulation by insulin-like growth factors. J Vet Pharmacol Ther 1995;18(2):141-149.

    48. Fortier LA, Mohammed HO, Lust G, et al. Insulin-like growth enhances cell-based repair of articular cartilage. J Bone Joint Surg (Br) 2004;84(2):276-288.

    49. Schramme MC, Clegg PD, Bird J, et al. Insulin-like growth factor I levels in synovial fluid of horses. Proc 14th Annu Sci Meet Eur Coll Vet Surg 2005:120-122.

    50. Schramme MC, Clegg PD, Bird J, et al. The effect of joint disease on the levels of insulin-like growth factor I binding proteins in synovial fluid of horses. Proc 14th Annu Sci Meet Eur Coll Vet Surg 2005:128-130.

    51. Burton-Wurster N, Liu W, Matthews GL, et al. TGF beta 1 and biglycan, decorin, and fibromodulin metabolism in canine cartilage. Osteoarthritis Cartilage 2003;11(3):167-176.

    52. Frisbie DD, Kawcak CW, McIlwraith CW. Evaluation of autologous conditioned serum using an experimental model of equine osteoarthritis. Proc Annu Conv AAEP 2005:1205, 2667.

    53. Marx RE. Platelet-rich plasma: evidence to support its use. J Oral Maxillofac Surg 2004;62:489-496.

    54. Sanchez M, Azofra J, Anitua E, et al. Plasma rich in growth factors to treat an articular cartilage avulsion: a case report. Med Sci Sports Exerc 2003;35:1648-1652.

    55. Carmona JU, Arguelles D, Climent F, et al. Report of the intraarticular treatment with platelet rich plasma in 7 horses with joint disease. Proc 14th Annu Sci Meet Eur Coll Vet Surg 2005:68-71.

    References »

    NEXT: Reading Room — Technical Large Animal Emergency Rescue

    CETEST This course is approved for 3.0 CE credits

    Start Test

    These Care Guides are written to help your clients understand common conditions. They are formatted to print and give to your clients for their information.

    Stay on top of all our latest content — sign up for the Vetlearn newsletters.
    • More
    Subscribe